Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-02-15 Option Award |
2025-02-19 5:29 pm |
N/A 2035-02-15 |
JOHNSON & JOHNSON | JNJ | REED JOHN C EVP, Innovative Medicine, R&D |
95,320 | $0 | 95,320 (Direct) |
View |
| 2025-02-15 Exercise |
2025-02-18 9:11 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | REED JOHN C EVP, Innovative Medicine, R&D |
1,350 | $0 | 18,240 (Direct) |
View |
| 2025-02-18 Tax Withholding |
2025-02-18 9:11 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | REED JOHN C EVP, Innovative Medicine, R&D |
385 | $156.15 | 18,240 (Direct) |
View |
| 2024-05-01 Tax Withholding(A) |
2024-10-31 5:57 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | REED JOHN C EVP, Innovative Medicine, R&D |
10,984 | $144.59 | 65,087 (Direct) |
View |
| 2024-05-01 Exercise(A) |
2024-10-31 5:57 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | REED JOHN C EVP, Innovative Medicine, R&D |
25,255 | $0 | 65,087 (Direct) |
View |
| 2024-05-01 Tax Withholding |
2024-05-03 4:31 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | REED JOHN C EVP, Innovative Medicine, R&D |
10,984 | $144.59 | 65,087 (Direct) |
View |
| 2024-05-01 Exercise |
2024-05-03 4:31 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | REED JOHN C EVP, Innovative Medicine, R&D |
22,255 | $0 | 65,087 (Direct) |
View |
| 2024-02-15 Option Award |
2024-02-20 5:55 pm |
N/A 2034-02-15 |
JOHNSON & JOHNSON | JNJ | REED JOHN C EVP, Innovative Medicine, R&D |
69,211 | $0 | 69,211 (Direct) |
View |
| 2023-05-01 Option Award |
2023-05-02 5:21 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | REED JOHN C EVP, Pharmaceuticals R&D |
75,765 | $0 | 75,765 (Direct) |
View |
Ownership |
2023-04-13 5:10 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | REED JOHN C EVP, Pharmaceuticals R&D |
0 | $0 | 306 (Direct) |
View |